Fisher & Paykel Healthcare
Market Cap
NZ$10.9b
Last Updated
2019/10/17 10:31 UTC
Data Sources
Company Financials +
Executive Summary
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems.
Snowflake
Fundamentals
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Fisher & Paykel Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
12.4%
FPH
6.6%
NZ Medical Equipment
1.8%
NZ Market
1 Year Return
33.8%
FPH
28.6%
NZ Medical Equipment
19.0%
NZ Market
Return vs Industry: FPH exceeded the NZ Medical Equipment industry which returned 28.6% over the past year.
Return vs Market: FPH exceeded the NZ Market which returned 19% over the past year.
Shareholder returns
| FPH | Industry | Market | |
|---|---|---|---|
| 7 Day | 12.4% | 6.6% | 1.8% |
| 30 Day | 11.8% | 8.3% | 3.4% |
| 90 Day | 19.0% | 8.6% | 3.3% |
| 1 Year | 36.5%33.8% | 30.9%28.6% | 24.2%19.0% |
| 3 Year | 119.5%106.5% | 66.1%58.1% | 56.8%36.3% |
| 5 Year | 287.3%248.0% | 181.4%157.4% | 105.2%59.1% |
Price Volatility Vs. Market
How volatile is Fisher & Paykel Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Are Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Investors Paying Above The Intrinsic Value?2 weeks ago | Simply Wall St
Is Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Salary Justified?3 weeks ago | Simply Wall St
Do Institutions Own Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Shares?Valuation
Is Fisher & Paykel Healthcare undervalued compared to its fair value and its price relative to the market?
52.02x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: FPH (NZ$19) is trading above our estimate of fair value (NZ$13.87)
Significantly Undervalued: FPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FPH is poor value based on its PE Ratio (52x) compared to the Medical Equipment industry average (29.6x).
PE vs Market: FPH is poor value based on its PE Ratio (52x) compared to the NZ market (18.4x).
Price to Earnings Growth Ratio
Low PEG Ratio: FPH is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: FPH is overvalued based on its PB Ratio (11.9x) compared to the XO Medical Equipment industry average (4.3x).
Next Steps
Future Growth
How is Fisher & Paykel Healthcare forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
13.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FPH's forecast earnings growth (13.9% per year) is above the savings rate (2.4%).
Earnings vs Market: FPH's earnings (13.9% per year) are forecast to grow faster than the NZ market (7% per year).
High Growth Earnings: FPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: FPH's revenue (10% per year) is forecast to grow faster than the NZ market (4.3% per year).
High Growth Revenue: FPH's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: FPH's Return on Equity is forecast to be high in 3 years time (28.5%)
Next Steps
Past Performance
How has Fisher & Paykel Healthcare performed over the past 5 years?
15.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: FPH's earnings have grown by 15.9% per year over the past 5 years.
Accelerating Growth: FPH's earnings growth over the past year (10%) is below its 5-year average (15.9% per year).
Earnings vs Industry: FPH earnings growth over the past year (10%) underperformed the Medical Equipment industry 21%.
Return on Equity
High ROE: FPH's Return on Equity (22.9%) is considered high.
Return on Assets
ROA vs Industry: FPH has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: FPH's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Fisher & Paykel Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: FPH's short term assets (NZ$455.3M) exceeds its short term liabilities (NZ$184.4M)
Long Term Liabilities: FPH's short term assets (455.3M) exceeds its long term liabilities (109.1M)
Debt to Equity History and Analysis
Debt Level: FPH's debt to equity ratio (9.5%) is considered satisfactory
Reducing Debt: FPH's debt to equity ratio has reduced from 27.7% to 9.5% over the past 5 years.
Debt Coverage: FPH's debt is well covered by operating cash flow (291.8%).
Interest Coverage: FPH earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: FPH has a high level of physical assets or inventory.
Debt Coverage by Assets: FPH's debt is covered by short term assets (assets are 5.245390x debt).
Next Steps
Dividend
What is Fisher & Paykel Healthcare's current dividend yield, its reliability and sustainability?
1.22%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: FPH's dividend (1.22%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (3.01%).
High Dividend: FPH's dividend (1.22%) is low compared to the top 25% of dividend payers in the NZ market (5.56%).
Stable Dividend: FPH is not paying a notable dividend for the NZ market, therefore no need to check if payments are stable.
Growing Dividend: FPH is not paying a notable dividend for the NZ market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: FPH is not paying a notable dividend for the NZ market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FPH's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
Next Steps
Management
What is the CEO of Fisher & Paykel Healthcare's salary, the management and board of directors tenure and is there insider trading?
3.2yrs
Average management tenure
CEO
Lewis Gradon (58yo)
3.5yrs
Tenure
NZ$2,678,092
Compensation
Mr. Lewis G. Gradon has been the Chief Executive Officer, Managing Director & Executive Director at Fisher & Paykel Healthcare Corporation Limited since April 1, 2016. Mr. Gradon served as the Senior Vice ...
CEO Compensation Analysis
Compensation vs. Market: Lewis's total compensation ($USD1.68M) is about average for companies of similar size in the NZ market ($USD1.33M).
Compensation vs Earnings: Lewis's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.2yrs
Average Tenure
Experienced Management: FPH's management team is considered experienced (3.2 years average tenure).
Board Age and Tenure
5.1yrs
Average Tenure
60.5yo
Average Age
Experienced Board: FPH's board of directors are considered experienced (5.1 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 4,913,527 |
| Max Price | NZ$17.00 |
Ownership Breakdown
Management Team
Lewis Gradon (58yo)
MD, CEO & Executive Director
- Tenure: 3.5yrs
- Compensation: NZ$2.68m
Paul Shearer
Senior Vice President of Sales & Marketing
- Tenure: 17.9yrs
Marcus Driller
Vice President of Corporate
- Tenure: 0yrs
Andrew Somervell
Vice President of Products & Technology
- Tenure: 3.5yrs
Debra Lumsden
VP of Human Resources & Privacy Officer
- Tenure: 2.8yrs
Rachel Reynolds
Senior Communications Manager
- Tenure: 0yrs
Lyndal York
Chief Financial Officer
- Tenure: 0.6yrs
Andrea Blackie
General Manager of Finance
- Tenure: 0.6yrs
Hayden Brown
Investor Relations Manager
- Tenure: 0yrs
Board Members
Lewis Gradon (58yo)
MD, CEO & Executive Director
- Tenure: 3.5yrs
- Compensation: NZ$2.68m
Mike Daniell (61yo)
Non-Executive Director
- Tenure: 17.9yrs
- Compensation: NZ$115.70k
Donal O’Dwyer (66yo)
Independent Non-Executive Director
- Tenure: 6.8yrs
- Compensation: NZ$157.16k
Neville Mitchell (60yo)
Independent Non-Executive Director
- Tenure: 0.9yrs
- Compensation: NZ$52.70k
Scott St John
Independent Non-Executive Director
- Tenure: 4yrs
- Compensation: NZ$143.80k
Geraldine McBride (58yo)
Independent Non Executive Director
- Tenure: 6.2yrs
- Compensation: NZ$98.85k
Tony Carter (61yo)
Board Chair
- Tenure: 7.5yrs
- Compensation: NZ$224.70k
Pip Greenwood
Non-Executive Director
- Tenure: 2.3yrs
- Compensation: NZ$121.30k
Company Information
Fisher & Paykel Healthcare Corporation Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fisher & Paykel Healthcare Corporation Limited
- Ticker: FPH
- Exchange: NZSE
- Founded: 1934
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NZ$10.912b
- Shares outstanding: 574.32m
- Website: https://www.fphcare.com
Number of Employees
Location
- Fisher & Paykel Healthcare Corporation Limited
- 15 Maurice Paykel Place
- East Tamaki
- Auckland
- 2013
- New Zealand
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FSPK.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| FPH | NZSE (New Zealand Stock Exchange) | Yes | Ordinary Shares | NZ | NZD | Jan 1992 |
| FPH | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jan 1992 |
| FPH | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jan 1992 |
| FSPK.Y | OTCPK (Pink Sheets LLC) | UNSPONSORD ADR | US | USD | Oct 2008 |
Biography
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems. It provides its products for use in respirator ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 10:31 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/03/31 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.